PDF(Pubmed)
Abstract：
UNASSIGNED: Derris reticulata Craib. and Glycyrrhiza glabra L., of the Fabaceae, have been used as active components in Thai herbal formulas for the treatment of fever and skin diseases.
UNASSIGNED: To evaluate the physicochemical and pharmacological properties of the developed herbal gel formulation containing the combined extract from D. reticulata stem wood and G. glabra root (RGF).
UNASSIGNED: The potential of the herbal gel formulation containing RGF (8% w/w) as the active ingredient was studied by evaluating the anti-inflammatory, antioxidant, and anti-Staphylococcus aureus activities using quantitative reverse transcription-polymerase chain reaction assay, spectrophotometric method, and broth microdilution technique, respectively. The reference standards for the biological testing included Nω-nitro-L-arginine (L-NA), ascorbic acid, catechin, and penicillin G. The stability study of the RGF herbal gel was performed by a heating-cooling test (at 45 °C for 24 h and at 4 °C for 24 h/1 cycle; for 6 cycles), and the bioactive marker compounds in the herbal gel were investigated by the HPLC technique.
UNASSIGNED: RGF showed promising pharmacological effects, particularly on its anti-inflammatory property (IC50 73.86 µg/mL), compared to L-NA (IC50 47.10 µg/mL). The RGF-containing gel demonstrated anti-inflammatory (IC50 3.59 mg/mL) and free radical scavenging effects (IC50 0.05-4.39 mg/mL), whereas it had no anti-S. aureus activity (MIC > 10 mg/mL). The active ingredient in the developed herbal gel significantly inhibited lipopolysaccharide-induced nitric oxide production by downregulating iNOS mRNA levels. The contents of the bioactive markers in the RGF gel (lupinifolin and glabridin) did not change significantly after stability testing.
UNASSIGNED: The RGF-containing gel has potential to be further developed as an herbal product for the treatment of skin inflammation.
UNASSIGNED: To evaluate the physicochemical and pharmacological properties of the developed herbal gel formulation containing the combined extract from D. reticulata stem wood and G. glabra root (RGF).
UNASSIGNED: The potential of the herbal gel formulation containing RGF (8% w/w) as the active ingredient was studied by evaluating the anti-inflammatory, antioxidant, and anti-Staphylococcus aureus activities using quantitative reverse transcription-polymerase chain reaction assay, spectrophotometric method, and broth microdilution technique, respectively. The reference standards for the biological testing included Nω-nitro-L-arginine (L-NA), ascorbic acid, catechin, and penicillin G. The stability study of the RGF herbal gel was performed by a heating-cooling test (at 45 °C for 24 h and at 4 °C for 24 h/1 cycle; for 6 cycles), and the bioactive marker compounds in the herbal gel were investigated by the HPLC technique.
UNASSIGNED: RGF showed promising pharmacological effects, particularly on its anti-inflammatory property (IC50 73.86 µg/mL), compared to L-NA (IC50 47.10 µg/mL). The RGF-containing gel demonstrated anti-inflammatory (IC50 3.59 mg/mL) and free radical scavenging effects (IC50 0.05-4.39 mg/mL), whereas it had no anti-S. aureus activity (MIC > 10 mg/mL). The active ingredient in the developed herbal gel significantly inhibited lipopolysaccharide-induced nitric oxide production by downregulating iNOS mRNA levels. The contents of the bioactive markers in the RGF gel (lupinifolin and glabridin) did not change significantly after stability testing.
UNASSIGNED: The RGF-containing gel has potential to be further developed as an herbal product for the treatment of skin inflammation.
摘要：
■网状网克雷布。和甘草，豆科，已被用作泰国草药配方中的活性成分，用于治疗发烧和皮肤病。
■评估开发的草药凝胶制剂的物理化学和药理特性，该制剂含有来自D.reticulata茎木和G.glabra根（RGF）的组合提取物。
■通过评估抗炎，研究了含有RGF（8％w/w）作为活性成分的草药凝胶制剂的潜力，抗氧化剂，使用定量逆转录-聚合酶链反应测定和抗金黄色葡萄球菌活性，分光光度法,和肉汤微量稀释技术，分别。生物测试的参考标准包括Nω-硝基-L-精氨酸（L-NA），抗坏血酸,儿茶素,和青霉素G。通过加热-冷却测试（在45°C下24小时和在4°C下24小时/1个循环；6个循环）进行RGF草药凝胶的稳定性研究，并通过HPLC技术研究了中药凝胶中的生物活性标记化合物。
■RGF显示出有希望的药理作用，特别是其抗炎特性（IC5073.86µg/mL），与L-NA（IC5047.10µg/mL）相比。含有RGF的凝胶具有抗炎作用（IC50为3.59mg/mL）和清除自由基的作用（IC50为0.05-4.39mg/mL），而它没有反S。金黄色葡萄球菌活性(MIC>10mg/mL)。开发的草药凝胶中的活性成分通过下调iNOSmRNA水平来显着抑制脂多糖诱导的一氧化氮产生。稳定性测试后，RGF凝胶中生物活性标记物（羽扇豆林和光吡啶）的含量没有显着变化。
■含RGF的凝胶具有作为治疗皮肤炎症的草药产品进一步开发的潜力。
■评估开发的草药凝胶制剂的物理化学和药理特性，该制剂含有来自D.reticulata茎木和G.glabra根（RGF）的组合提取物。
■通过评估抗炎，研究了含有RGF（8％w/w）作为活性成分的草药凝胶制剂的潜力，抗氧化剂，使用定量逆转录-聚合酶链反应测定和抗金黄色葡萄球菌活性，分光光度法,和肉汤微量稀释技术，分别。生物测试的参考标准包括Nω-硝基-L-精氨酸（L-NA），抗坏血酸,儿茶素,和青霉素G。通过加热-冷却测试（在45°C下24小时和在4°C下24小时/1个循环；6个循环）进行RGF草药凝胶的稳定性研究，并通过HPLC技术研究了中药凝胶中的生物活性标记化合物。
■RGF显示出有希望的药理作用，特别是其抗炎特性（IC5073.86µg/mL），与L-NA（IC5047.10µg/mL）相比。含有RGF的凝胶具有抗炎作用（IC50为3.59mg/mL）和清除自由基的作用（IC50为0.05-4.39mg/mL），而它没有反S。金黄色葡萄球菌活性(MIC>10mg/mL)。开发的草药凝胶中的活性成分通过下调iNOSmRNA水平来显着抑制脂多糖诱导的一氧化氮产生。稳定性测试后，RGF凝胶中生物活性标记物（羽扇豆林和光吡啶）的含量没有显着变化。
■含RGF的凝胶具有作为治疗皮肤炎症的草药产品进一步开发的潜力。
